Physicians' Academy for Cardiovascular Education

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer

Video navigation menu

  • Current medication to improve morbidity/mortality in HFrEF 0:00
  • PARADIGM-HF trial: LCZ696 compared with enalapril with respect to morbidity/mortality 0:37
  • ATMOSPHERE trial - aliskiren compared with enalapril 1:42
  • Potassium-binding drugs to lower hyperkalemia 2:19
  • Conclusion - cornerstone drug therapy in HFrEF and new treatment modalities 3:11

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: